94 related articles for article (PubMed ID: 27773933)
1. Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia.
Lohmann G; Vasyutina E; Bloehdorn J; Reinart N; Schneider JI; Babu V; Knittel G; Crispatzu G; Mayer P; Prinz C; Muenzner JK; Biersack B; Efremov DG; Chessa L; Herling CD; Stilgenbauer S; Hallek M; Schobert R; Reinhardt HC; Schumacher B; Herling M
Leukemia; 2017 May; 31(5):1177-1186. PubMed ID: 27773933
[TBL] [Abstract][Full Text] [Related]
2. Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease.
Zecevic A; Sampath D; Ewald B; Chen R; Wierda W; Plunkett W
Clin Cancer Res; 2011 Jul; 17(14):4731-41. PubMed ID: 21632856
[TBL] [Abstract][Full Text] [Related]
3. Targeting DNA repair with aphidicolin sensitizes primary chronic lymphocytic leukemia cells to purine analogs.
Starczewska E; Beyaert M; Michaux L; Vekemans MC; Saussoy P; Bol V; Arana Echarri A; Smal C; Van Den Neste E; Bontemps F
Oncotarget; 2016 Jun; 7(25):38367-38379. PubMed ID: 27223263
[TBL] [Abstract][Full Text] [Related]
4. Indole-3-Carbinol Synergizes with and Restores Fludarabine Sensitivity in Chronic Lymphocytic Leukemia Cells Irrespective of p53 Activity and Treatment Resistances.
Perez-Chacon G; Martinez-Laperche C; Rebolleda N; Somovilla-Crespo B; Muñoz-Calleja C; Buño I; Zapata JM
Clin Cancer Res; 2016 Jan; 22(1):134-45. PubMed ID: 26324744
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells.
Pepper C; Lowe H; Fegan C; Thurieau C; Thurston DE; Hartley JA; Delavault P
Br J Cancer; 2007 Jul; 97(2):253-9. PubMed ID: 17579621
[TBL] [Abstract][Full Text] [Related]
6. Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia.
Moussay E; Palissot V; Vallar L; Poirel HA; Wenner T; El Khoury V; Aouali N; Van Moer K; Leners B; Bernardin F; Muller A; Cornillet-Lefebvre P; Delmer A; Duhem C; Ries F; van Dyck E; Berchem G
Mol Cancer; 2010 May; 9():115. PubMed ID: 20487546
[TBL] [Abstract][Full Text] [Related]
7. Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia.
Pandzic T; Larsson J; He L; Kundu S; Ban K; Akhtar-Ali M; Hellström AR; Schuh A; Clifford R; Blakemore SJ; Strefford JC; Baumann T; Lopez-Guillermo A; Campo E; Ljungström V; Mansouri L; Rosenquist R; Sjöblom T; Hellström M
Clin Cancer Res; 2016 Dec; 22(24):6217-6227. PubMed ID: 26957556
[TBL] [Abstract][Full Text] [Related]
8. The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia.
Kaufman KL; Jenkins Y; Alomari M; Mirzaei M; Best OG; Pascovici D; Mactier S; Mulligan SP; Haynes PA; Christopherson RI
Oncotarget; 2015 Dec; 6(38):40981-97. PubMed ID: 26556860
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine.
Huang P; Sandoval A; Van Den Neste E; Keating MJ; Plunkett W
Leukemia; 2000 Aug; 14(8):1405-13. PubMed ID: 10942236
[TBL] [Abstract][Full Text] [Related]
10. Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia.
Merkel O; Wacht N; Sifft E; Melchardt T; Hamacher F; Kocher T; Denk U; Hofbauer JP; Egle A; Scheideler M; Schlederer M; Steurer M; Kenner L; Greil R
Leukemia; 2012 Dec; 26(12):2508-16. PubMed ID: 22743622
[TBL] [Abstract][Full Text] [Related]
11. DNA polymerase ν gene expression influences fludarabine resistance in chronic lymphocytic leukemia independently of p53 status.
Grgurevic S; Montilla-Perez P; Bradbury A; Gilhodes J; Queille S; Pelofy S; Bancaud A; Filleron T; Ysebaert L; Récher C; Laurent G; Fournié JJ; Cazaux C; Quillet-Mary A; Hoffmann JS
Haematologica; 2018 Jun; 103(6):1038-1046. PubMed ID: 29567785
[TBL] [Abstract][Full Text] [Related]
12. [Research advance on fludarabine resistance mechanisms in chronic lymphocytic leukemia cells].
Yao L; Xu W; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):821-4. PubMed ID: 20561458
[TBL] [Abstract][Full Text] [Related]
13. The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill.
Pepper CJ; Hambly RM; Fegan CD; Delavault P; Thurston DE
Cancer Res; 2004 Sep; 64(18):6750-5. PubMed ID: 15374993
[TBL] [Abstract][Full Text] [Related]
14. Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal.
Moufarij MA; Sampath D; Keating MJ; Plunkett W
Blood; 2006 Dec; 108(13):4187-93. PubMed ID: 16954499
[TBL] [Abstract][Full Text] [Related]
15. Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells.
Soares DG; Machado MS; Rocca CJ; Poindessous V; Ouaret D; Sarasin A; Galmarini CM; Henriques JA; Escargueil AE; Larsen AK
Mol Cancer Ther; 2011 Aug; 10(8):1481-9. PubMed ID: 21622731
[TBL] [Abstract][Full Text] [Related]
16. Valproic acid enhances fludarabine-induced apoptosis mediated by ROS and involving decreased AKT and ATM activation in B-cell-lymphoid neoplastic cells.
Yoon JY; Ishdorj G; Graham BA; Johnston JB; Gibson SB
Apoptosis; 2014 Jan; 19(1):191-200. PubMed ID: 24057147
[TBL] [Abstract][Full Text] [Related]
17. Targeting base excision repair suggests a new therapeutic strategy of fludarabine for the treatment of chronic lymphocytic leukemia.
Bulgar AD; Snell M; Donze JR; Kirkland EB; Li L; Yang S; Xu Y; Gerson SL; Liu L
Leukemia; 2010 Oct; 24(10):1795-9. PubMed ID: 20811400
[No Abstract] [Full Text] [Related]
18. Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas.
Laroche A; Chaire V; Le Loarer F; Algéo MP; Rey C; Tran K; Lucchesi C; Italiano A
J Hematol Oncol; 2017 Apr; 10(1):84. PubMed ID: 28399901
[TBL] [Abstract][Full Text] [Related]
19. Trabectedin derails transcription-coupled nucleotide excision repair to induce DNA breaks in highly transcribed genes.
Son K; Takhaveev V; Mor V; Yu H; Dillier E; Zilio N; Püllen NJL; Ivanov D; Ulrich HD; Sturla SJ; Schärer OD
Nat Commun; 2024 Feb; 15(1):1388. PubMed ID: 38360910
[TBL] [Abstract][Full Text] [Related]
20. Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance.
Englinger B; Mair M; Miklos W; Pirker C; Mohr T; van Schoonhoven S; Lötsch D; Körner W; Ferk F; Knasmüller S; Heffeter P; Keppler BK; Grusch M; Berger W
Br J Cancer; 2017 Feb; 116(4):489-500. PubMed ID: 28095394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
